- Home
- OB vs ATXS Comparison
OB vs ATXS Comparison
Compare OB & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- ATXS
- Stock Information
- Founded
- OB 2006
- ATXS 2008
- Country
- OB United States
- ATXS United States
- Employees
- OB N/A
- ATXS N/A
- Industry
- OB Industrial Machinery/Components
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- OB Industrials
- ATXS Health Care
- Exchange
- OB Nasdaq
- ATXS Nasdaq
- Market Cap
- OB 441.8M
- ATXS 401.2M
- IPO Year
- OB 2021
- ATXS 2015
- Fundamental
- Price
- OB $4.02
- ATXS $7.14
- Analyst Decision
- OB Buy
- ATXS Strong Buy
- Analyst Count
- OB 6
- ATXS 6
- Target Price
- OB $6.80
- ATXS $26.67
- AVG Volume (30 Days)
- OB 501.3K
- ATXS 223.1K
- Earning Date
- OB 02-27-2025
- ATXS 03-11-2025
- Dividend Yield
- OB N/A
- ATXS N/A
- EPS Growth
- OB N/A
- ATXS N/A
- EPS
- OB N/A
- ATXS N/A
- Revenue
- OB $889,875,000.00
- ATXS N/A
- Revenue This Year
- OB $30.47
- ATXS N/A
- Revenue Next Year
- OB N/A
- ATXS N/A
- P/E Ratio
- OB N/A
- ATXS N/A
- Revenue Growth
- OB N/A
- ATXS N/A
- 52 Week Low
- OB $3.58
- ATXS $5.73
- 52 Week High
- OB $7.87
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- OB 23.52
- ATXS 55.99
- Support Level
- OB $3.89
- ATXS $5.73
- Resistance Level
- OB $4.41
- ATXS $6.88
- Average True Range (ATR)
- OB 0.41
- ATXS 0.42
- MACD
- OB -0.16
- ATXS 0.10
- Stochastic Oscillator
- OB 4.78
- ATXS 92.16
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.